Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVX836 + quadrivalent inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Osivax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
OVX836 + quadrivalent inactivated influenza vaccine (QIV) is a concomitant immunization regimen being developed by Osivax. OVX836 is a recombinant protein vaccine candidate that targets the highly conserved internal nucleoprotein (NP) of the influenza virus, utilizing a self-assembling nanoparticle platform to induce a broad T-cell response. The QIV component consists of standard seasonal inactivated vaccines (such as Fluarix Tetra or Afluria Quad) that target the surface hemagglutinin (HA) proteins of four specific influenza strains. The combination aims to provide both the strain-specific protection of traditional vaccines and the broad, cross-reactive protection against multiple influenza A and B strains offered by the NP-targeting OVX836. The regimen is administered as two separate injections into opposite arms.
- Brand names
- Fluarix TetraAfluria Quad
- Other names
- OVX836 + QIV
02
Targets
HA (Hemagglutinin)NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on OVX836 + quadrivalent inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVX836 + quadrivalent inactivated influenza vaccine.